Search Results - david+mendelowitz

4 Results Sort By:
Combating Opioid-Induced Respiratory Depression Using Setmelanotide
The opioid crisis is a serious public health crisis in the United States. Mortality from opioid overdose increased by roughly ten times from 1999 to 2021. The primary cause of death is due to opioid-induced respiratory depression (OIRD). Currently, Naloxone and Nalmefene are actively used to reverse OIRD in emergency settings and by first responders....
Published: 7/30/2024   |   Inventor(s): Vsevolod Polotsky, David Mendelowitz, O Aung, Mateus Ramos Amorim, Joan Escobar
Keywords(s):  
Category(s): Technology Classifications > Therapeutics > Small Molecules, Technology Classifications > Therapeutics > Repurposed Drugs
Oxytocin reverses respiratory depression induced by xylazine-laced fentanyl
The opioid crisis is a serious public health issue in the United States. Synthetic opioids such as fentanyl have contributed significantly to this crisis. However, recent samples have shown the presence of xylazine, a veterinary tranquilizer, with fentanyl. Xylazine was found in almost 80% of fentanyl samples in Maryland between 2021 and 2022. Naloxone...
Published: 10/29/2024   |   Inventor(s): Joan Escobar, Olga dergacheva, David Mendelowitz
Keywords(s):  
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Therapeutics > Repurposed Drugs
Intranasal leptin to treat opioid-induced respiratory depression (OIRD) in obese patients
­Respiratory depression is the leading cause of morbidity and mortality associated with opioids. Patients with obesity experience pain and need opioids more frequently than normal-weight individuals. Chronic consumption of opioids is associated with addiction, physical dependence, and tolerance. Tolerance leads to requirement of higher doses of...
Published: 9/11/2024   |   Inventor(s): David Mendelowitz, Vsevolod Polotsky, Carla Freire
Keywords(s):  
Category(s): Technology Classifications > Therapeutics
Intranasal Oxytocin Therapy for Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a health risk that occurs in 24% of males and 9% of females in the United States. OSA can lead to several cardiovascular diseases including hypertension, arrhythmia, and stroke. Continuous positive airway pressure (CPAP) treatments often fail due to low compliance. GW Researchers developed an intranasal oxytocin administration...
Published: 7/30/2024   |   Inventor(s): David Mendelowitz, Heather Jameson, Vivek Jain, Jay Kimbro
Keywords(s):  
Category(s): Technology Classifications > Medical Devices > Cardiology, Technology Classifications > Therapeutics > Proteins and Peptides